<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00319189</url>
  </required_header>
  <id_info>
    <org_study_id>Starlix in RTR</org_study_id>
    <nct_id>NCT00319189</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Nateglinide Treatment in Renal Transplant Recipients</brief_title>
  <official_title>Efficacy and Safety of Nateglinide Treatment in Renal Treatment Recipients With Post Transplant Diabetes Mellitus or Impaired Glucose Tolerance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oslo School of Pharmacy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oslo School of Pharmacy</source>
  <brief_summary>
    <textblock>
      The objective of the present study is to evaluate both the efficacy and safet of nateglinide
      in renal transplanta recipients with posttransplant diabetes mellitus or impaired glucose
      tolerance. Primarily will the change in glucose tolerance and acute insuline responce be
      addressed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date>November 2003</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose tolerance</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Insuline release</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose oxidation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial hyperlipidemia</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1C</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma nitric oxide</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma endothelin-1</measure>
  </secondary_outcome>
  <enrollment>15</enrollment>
  <condition>Renal Transplant Recipients</condition>
  <condition>Posttransplant Diabetes Mellitus</condition>
  <condition>Posttransplant Impaired Glucose Tolerance</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nateglinide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Reduced glucose tolerance (fasting glucose &lt; 6.1 mmol/L AND 2 hour glucose between 6.7
             and 9.9 mmol/L) or posttransplant diabetes mellitus (fasting glucose &gt; 6.1 mmol/L OR 2
             hour glucose between &gt;= 10.0 mmol/L)

          -  Stable patients fgollowing renal transplantation, less than 25% variation in serum
             creatinine last week and serum creatinine &lt; 200 micromol/L

        Exclusion Criteria:

          -  Patients with indulin dependent diabetes mellitus before or after transplantation

          -  Planned change in daily prednisolone dose during the study period

          -  Haemoglobin &lt; 8g/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Trond Jenssen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rikshospitalet, Section of Nephrology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rikshospitalet, Section of Nephrology</name>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2006</study_first_submitted>
  <study_first_submitted_qc>April 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2006</study_first_posted>
  <last_update_submitted>May 9, 2006</last_update_submitted>
  <last_update_submitted_qc>May 9, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2006</last_update_posted>
  <keyword>Nateglinide</keyword>
  <keyword>Renal</keyword>
  <keyword>Kidney</keyword>
  <keyword>Transplantation</keyword>
  <keyword>Diabets</keyword>
  <keyword>Glucose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nateglinide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

